Kazmira Therapeutics Partners With CareValidate to Expand Access to Prescription, THC-Free CBD Therapy Across the U.S.
Kazmira Therapeutics, the company behind Kazmira Pharmacy and the Cope Now telehealth platform, has announced a partnership with CareValidate, a digital health infrastructure provider that supports telehealth brands, provider networks, prescription routing, and pharmacy fulfillment across the United States. The collaboration is designed to expand patient access to Prescription Cannabis Therapy through a structured telemedicine pathway that connects licensed clinicians, pharmaceutical-grade cannabidiol (CBD) formulations, and licensed pharmacy services.
Under the partnership, patients evaluated by independent, licensed clinicians through CareValidate-powered telehealth programs may receive prescriptions for compounded CBD formulations when clinically appropriate. The formulations are designed to be non-intoxicating and THC-free, are prepared by a licensed 503A pharmacy against a prescription issued by a licensed clinician, and use Kazmira’s pharmaceutical-grade active pharmaceutical ingredient (API).
The partnership combines Kazmira’s expertise in cannabinoid formulation and pharmacy services with CareValidate’s digital infrastructure for connecting patients, clinicians, and pharmacies. Prescriptions are routed through the CareValidate platform to Kazmira Pharmacy and other approved pharmacies, where the medication is compounded according to the prescribed dose and shipped directly to the patient.
According to the companies, this prescription-based access pathway is immediately available across all 50 U.S. states, subject to applicable clinical, pharmacy, and state requirements. Telehealth programs offering Prescription Cannabis Therapy through the CareValidate platform are expected to begin enrolling patients in October 2026.
The announcement comes as the U.S. hemp-derived cannabinoid market faces anticipated regulatory changes. Kazmira and CareValidate are positioning their partnership around a healthcare-centered approach that emphasizes clinician evaluation, prescription-based dosing, pharmaceutical-grade ingredients, and regulated pharmacy fulfillment rather than the consumer-directed purchasing model commonly associated with retail CBD products.
Partnership Introduces a Prescription-Based Model for CBD Access
CBD is a cannabinoid derived from cannabis plants that does not produce the characteristic intoxicating effects associated with tetrahydrocannabinol (THC). CBD products are widely marketed in consumer settings, including oils, capsules, and other formulations. However, the quality, composition, concentration, and intended use of retail products can vary considerably.
Kazmira Therapeutics and CareValidate aim to address some of these challenges by establishing a pathway through which eligible patients can access compounded CBD following an evaluation by a licensed clinician.
The model places clinical assessment and prescription decisions at the center of the process. Rather than selecting a retail product and determining a dose independently, patients enter a telemedicine pathway in which a clinician evaluates their circumstances and determines whether a prescription is appropriate.
When prescribed, the CBD formulation is prepared by a licensed 503A pharmacy using Kazmira’s pharmaceutical-grade API. The pharmacy compounds the medication according to the prescribed dose and arranges shipment directly to the patient.
CareValidate provides the digital infrastructure that connects the different participants in this process. Its platform supports telehealth programs, provider networks, prescription routing, and pharmacy fulfillment, enabling healthcare brands to coordinate services through a connected system.
Kazmira contributes its cannabinoid formulation capabilities and pharmacy operations, while CareValidate supplies the technology infrastructure that helps connect patients with clinicians and participating pharmacies.
The companies believe this arrangement can make prescription-based CBD access more structured and consistent. It also creates a framework in which clinical oversight, formulation standards, and pharmacy dispensing are integrated into a single patient pathway.
The partnership does not mean that CBD is appropriate for every patient or condition. Prescription decisions remain dependent on individual clinical evaluations, and the suitability of a compounded formulation must be determined by the treating clinician.
Regulatory Changes Reshape the Hemp-Derived CBD Market
The partnership announcement comes amid significant anticipated changes to the regulatory environment for hemp-derived cannabinoid products in the United States.
According to the companies, Congress has closed the hemp loophole that previously enabled a broad range of intoxicating hemp-derived products to enter the over-the-counter market. They state that federal enforcement is expected to begin in December 2026, following a November deadline referenced in their announcement.
The companies expect these changes to affect a substantial portion of the existing retail cannabinoid market. However, the precise impact will depend on the final applicable statutory definitions, implementation requirements, and regulatory interpretation.
Kazmira argues that its THC-free formulations and prescription-only model position the company to operate within a more healthcare-oriented framework as the market adjusts to the changing rules.
The distinction between consumer wellness products and prescription-based therapies is central to the partnership’s approach. Retail CBD products are generally purchased directly by consumers, whereas the model introduced by Kazmira and CareValidate incorporates clinical assessment, prescription issuance, pharmacy compounding, and direct fulfillment.
These differences may become increasingly relevant as cannabinoid businesses review their products, distribution channels, payment processing arrangements, and advertising strategies in response to regulatory changes.
Nevertheless, a prescription-based model does not automatically establish that every compounded CBD preparation is FDA-approved or that every product currently sold at retail will become unlawful. Applicable requirements depend on the product, its composition, its intended use, and the governing federal and state laws.
The companies’ stated strategy is to provide a regulated healthcare pathway for patients seeking CBD while helping businesses adapt to changes affecting the broader hemp and cannabinoid industries.
Addressing Concerns About CBD Dosing and Product Consistency
A major element of the partnership is its focus on the gap between consumer CBD use and medically supervised dosing.
Kazmira and CareValidate cite research suggesting that 54% of active CBD users take less than 50 milligrams per day. They contrast this finding with clinical research involving doses of 200 to 400 milligrams, which they reference as a range associated with efficacy in certain research contexts.
These figures should not be interpreted as establishing a universally effective CBD dose. The appropriate dose depends on the condition being treated, the formulation, the available clinical evidence, potential drug interactions, and individual patient characteristics. Evidence supporting CBD also differs by indication, and results from one clinical setting cannot automatically be applied to another.
The companies argue that the retail market can leave consumers uncertain about the concentration, composition, and appropriate use of the products they purchase. Without clinical guidance, individuals may have difficulty determining whether a particular product is suitable for their needs or how its use should be monitored.
Prescription Cannabis Therapy is intended to replace that consumer-led process with an approach centered on clinician evaluation and individualized prescribing.
Under this model, the clinician determines whether treatment is appropriate and establishes the prescribed dose. A participating pharmacy then compounds and dispenses the formulation according to the prescription.
This process is designed to improve coordination between clinical decision-making and medication preparation. It also creates an opportunity for patient education and follow-up, allowing clinicians to assess treatment suitability and address concerns as appropriate.
Pharmaceutical-grade ingredients and standardized formulation processes may help support product consistency. However, the use of a pharmaceutical-grade API does not, by itself, establish the clinical effectiveness or safety of every compounded formulation.
Compounded medications also have a different regulatory status from FDA-approved drugs. The companies’ prescription-based approach therefore should be understood as a framework for clinician-directed access, rather than a blanket claim that all CBD formulations are approved treatments for specific diseases.
Kazmira and CareValidate Emphasize Clinical Oversight
The companies’ leadership teams describe the partnership as part of a broader effort to bring cannabinoid products into a more structured healthcare environment.
Priyanka Sharma, Ph.D., Co-Founder and Co-CEO of Kazmira Therapeutics, said the company has spent the past decade working to demonstrate that cannabinoids can be incorporated into a more rigorous, healthcare-centered model.
“What is exciting about this partnership is that we are no longer building that vision alone,” Sharma said. She added that healthcare companies are developing infrastructure to connect patients, clinicians, technology platforms, and licensed pharmacies, describing the development as part of a wider movement.
The statement highlights Kazmira’s emphasis on integrating cannabinoid products with established healthcare processes rather than relying exclusively on consumer retail distribution.
Pulak Sharma, Co-Founder and Co-CEO of Kazmira Therapeutics, also emphasized the collaborative nature of the initiative, noting that the partnership brings together capabilities developed by companies working across different parts of the healthcare ecosystem.
For Kazmira, the arrangement provides a way to connect its formulation and pharmacy expertise with a technology platform capable of coordinating telehealth programs and prescription fulfillment.
CareValidate’s leadership similarly emphasized the importance of clinical oversight and pharmacy involvement.
John Hayde, Co-Founder and CEO of CareValidate, said millions of Americans already use CBD, while many do so without clinician involvement or dosing guidance.
“Our job is to make that care better with a licensed provider, a real prescription, a pharmaceutical-grade formulation and a pharmacy that ships it to the patient’s door,” Hayde said.
He described the partnership as a combination of complementary capabilities, with Kazmira providing the cannabinoid ingredient and pharmacy services and CareValidate supplying the digital infrastructure needed to connect those services with patients.
The collaboration is intended to help patients access prescription-based CBD through telehealth programs while maintaining the clinical and pharmacy processes required by the model.
Jiten Chhabra, MD, Co-Founder and Chief Medical Officer of CareValidate, also highlighted the role of eligibility screening, patient-provider relationships, monitoring protocols, and follow-up.
According to Chhabra, cannabinoid therapy has operated outside the healthcare system for an extended period, leaving consumers to make decisions about products and dosing with limited professional guidance.
He said Kazmira brings a pharmaceutical approach that includes a purified, THC-free active ingredient, standardized formulations, defined dosing, and clinician education.
Combined with CareValidate’s telemedicine infrastructure, these elements are intended to establish a framework in which patients can be assessed and monitored by licensed healthcare providers.
The model’s clinical safeguards will be important to its implementation. As with other medications, CBD may cause adverse effects and interact with other drugs. Clinicians must consider these factors when determining whether treatment is appropriate, and patients should receive guidance about potential risks and the need for follow-up.
Storefront Partner Program Targets Hemp and Cannabinoid Businesses
Beyond patient access, Kazmira and CareValidate are inviting hemp and cannabinoid businesses to apply for participation in a Storefront Partner program.
The initiative is intended to help businesses that may face disruption from anticipated regulatory changes, including potential difficulties involving payment processing and advertising accounts.
Through the program, participating brands can offer customers access to CBD through a branded telehealth storefront operating within a regulated prescription-based framework.
The companies are positioning the initiative as an opportunity for existing cannabinoid businesses to adapt their commercial models rather than relying exclusively on conventional retail sales.
Businesses operating in the hemp-derived cannabinoid market may need to reassess product portfolios, marketing claims, distribution arrangements, and compliance processes as new requirements take effect. A telehealth storefront could provide another route for connecting interested customers with licensed clinicians and participating pharmacies.
However, participation in such a program would not exempt a business from applicable legal or regulatory requirements. Product eligibility, pharmacy operations, clinical practices, advertising, and distribution must remain consistent with the rules governing each activity.
Brands interested in the Storefront Partner program can find additional information at CareValidate’s Prescription CBD page.
The program extends the partnership beyond direct patient services by offering businesses a potential route into prescription-based cannabinoid access.
Nationwide Telehealth Access and Implementation Timeline
Kazmira and CareValidate state that prescription, THC-free CBD access through their partnership is available across all 50 U.S. states, subject to applicable requirements.
Telehealth programs offering Prescription Cannabis Therapy through CareValidate are expected to begin enrolling patients in October 2026. Through these programs, patients can be evaluated by independent licensed clinicians, who determine whether a prescription is appropriate.
When a prescription is issued, it is routed through CareValidate’s platform to Kazmira Pharmacy or another approved pharmacy participating in the program. The medication is then compounded according to the prescription and shipped directly to the patient.
The structure is designed to coordinate clinical evaluation, prescribing, dispensing, and fulfillment through a connected digital pathway. It also allows CareValidate to support telehealth brands and provider networks without requiring each participating brand to develop all the underlying infrastructure independently.
Patients and businesses seeking additional information about Prescription Cannabis Therapy can visit CareValidate. Individuals considering CBD treatment should consult a qualified healthcare professional to discuss the available evidence, possible risks, drug interactions, and whether a particular treatment approach is appropriate.
Outlook: Building a Healthcare-Centered Cannabinoid Model
The partnership between Kazmira Therapeutics and CareValidate represents an effort to connect cannabinoid formulation expertise with telehealth technology and licensed pharmacy services.
By combining Kazmira’s pharmaceutical-grade CBD ingredient and pharmacy capabilities with CareValidate’s provider network support, prescription routing, and fulfillment infrastructure, the companies aim to establish a more structured pathway for prescription-based CBD access.
The collaboration also reflects the companies’ expectations that regulatory changes will reshape the hemp-derived cannabinoid market, prompting businesses to examine alternatives to traditional over-the-counter distribution.
Its principal differentiators are the emphasis on clinician evaluation, individualized prescriptions, pharmacy compounding, and direct medication delivery. The Storefront Partner program extends that approach to businesses seeking new ways to serve customers amid changing market requirements.
The long-term significance of the initiative will depend on its implementation, regulatory compliance, patient access, clinical oversight, and the strength of the evidence supporting particular CBD uses. Prescription-based access alone does not establish that CBD is effective for every condition, and compounded formulations should not be confused with FDA-approved medications.
Nevertheless, the partnership establishes a framework through which Kazmira and CareValidate intend to connect patients, clinicians, technology platforms, and pharmacies in a coordinated cannabinoid care model. As the regulatory environment evolves, the companies aim to make prescription-based, THC-free CBD access available through telehealth while helping participating businesses adapt to a changing healthcare and cannabinoid marketplace.
About Kazmira Therapeutics
Kazmira Therapeutics is the first vertically integrated cannabinoid company in the United States, combining pharmaceutical-grade cannabidiol API manufacturing, a licensed 503A compounding pharmacy (Kazmira Pharmacy), and a clinician-led telehealth platform (Cope Now). Headquartered in Watkins, Colorado, Kazmira also operates 1Cannabis, 1cannabiscares.com, the clinician and patient education platform for prescription cannabinoid pharmacology. Kazmira’s pharmaceutical-grade standards position the company as a compliant operator ahead of the December 2026 federal enforcement deadline for hemp-derived cannabinoid products. Learn more at kazmiratx.com.
About CareValidate
CareValidate is the compliance infrastructure behind some of the fastest-growing telehealth brands in the country, including care pathways in menopause, weight loss, longevity & wellness, dermatology, and erectile dysfunction. The platform gives digital health companies, retailers, and wellness brands everything needed to launch and scale virtual care compliantly, from a nationwide licensed provider network and pharmacy fulfillment to AI-powered patient engagement, lab diagnostics, and an API-first architecture that integrates with existing systems. With HIPAA, SOC 2 Type II, and LegitScript compliance built into the platform from the ground up, CareValidate helps telehealth brands go live in an average of 30 days and achieve 3:1 ROI in the first year. Learn more at carevalidate.com.